Acadia Pharmaceuticals Inc (NASDAQ:ACAD) shares, rose in value on Friday, March 28, with the stock price down by -0.70% to the previous day’s close as strong demand from buyers drove the stock to $17.07.
Actively observing the price movement in the last trading, the stock closed the session at $17.19, falling within a range of $16.92 and $17.2204. The value of beta (5-year monthly) was 0.427 whereas the PE ratio was 12.55 over 12-month period. Referring to stock’s 52-week performance, its high was $20.68, and the low was $14.15. On the whole, ACAD has fluctuated by -11.74% over the past month.
With the market capitalization of Acadia Pharmaceuticals Inc currently standing at about $2.85 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-25.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 1.06B, with a low estimate of 224.78M and a high estimate of 255M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 239.34M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ACAD’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 6.40, with the price of ACAD currently trading nearly -1.46% and -6.65% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.84, while the 7-day volatility ratio is showing 2.15% which for the 30-day chart, stands at 3.38%. Furthermore, Acadia Pharmaceuticals Inc (ACAD)’s beta value is 0.52, and its average true range (ATR) is 0.59.
A comparison of Acadia Pharmaceuticals Inc (ACAD) with its peers suggests the former has fared considerably weaker in the market. ACAD showed an intraday change of -0.70% in last session, and over the past year, it shrunk by -4.05%%.
Data on historical trading for Acadia Pharmaceuticals Inc (NASDAQ:ACAD) indicates that the trading volumes over the past 10 days have averaged 1.49 and over the past 3 months, they’ve averaged 2.54 million. According to company’s latest data on outstanding shares, there are 166.71 million shares outstanding.
Nearly 0.77% of Acadia Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 98.27% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.43 million shares as on 2025-03-14, resulting in a short ratio of 8.32. According to the data, the short interest in Acadia Pharmaceuticals Inc (ACAD) stood at 1167.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 15.21 million. The stock has fallen by -6.98% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ACAD stock heading into the next quarter.
